Genetic Testing and Results in a Population-Based Cohort of Breast Cancer Patients and Ovarian Cancer Patients.

PURPOSE Genetic testing for cancer risk has expanded rapidly. We examined clinical genetic testing and results among population-based patients with breast and ovarian cancer. METHODS The study included all women 20 years of age or older diagnosed with breast or ovarian cancer in California and Georgia between 2013 and 2014 and reported to the SEER registries covering the entire state populations. SEER data were linked to results from four laboratories that performed nearly all germline cancer genetic testing. Testing use and results were analyzed at the gene level. RESULTS There were 77,085 patients with breast cancer and 6,001 with ovarian cancer. Nearly one quarter of those with breast cancer (24.1%) and one third of those with ovarian cancer (30.9%) had genetic test results. Among patients with ovarian cancer, testing was lower in blacks (21.6%; 95% CI, 18.1% to 25.4%; v whites, 33.8%; 95% CI, 32.3% to 35.3%) and uninsured patients (20.8%; 95% CI, 15.5% to 26.9%; v insured patients, 35.3%; 95% CI, 33.8% to 36.9%). Prevalent pathogenic variants in patients with breast cancer were BRCA1 (3.2%), BRCA2 (3.1%), CHEK 2 (1.6%), PALB2 (1.0%), ATM (0.7%), and NBN (0.4%); in patients with ovarian cancer, prevalent pathogenic variants were BRCA1 (8.7%), BRCA2 (5.8%), CHEK2 (1.4%), BRIP1 (0.9%), MSH2 (0.8%), and ATM (0.6%). Racial/ethnic differences in pathogenic variants included BRCA1 (ovarian cancer: whites, 7.2%; 95% CI, 5.9% to 8.8%; v Hispanics, 16.1%; 95% CI, 11.8% to 21.2%) and CHEK2 (breast cancer: whites, 2.3%; 95% CI, 1.8% to 2.8%; v blacks, 0.1%; 95% CI, 0% to 0.8%). When tested for all genes that current guidelines designate as associated with their cancer type, 7.8% of patients with breast cancer and 14.5% of patients with ovarian cancer had pathogenic variants. CONCLUSION Clinically-tested patients with breast and ovarian cancer in two large, diverse states had 8% to 15% prevalence of actionable pathogenic variants. Substantial testing gaps and disparities among patients with ovarian cancer are targets for improvement.

[1]  R. Jagsi,et al.  Gaps in Incorporating Germline Genetic Testing Into Treatment Decision-Making for Early-Stage Breast Cancer. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  Diana M Eccles,et al.  The Angelina Jolie effect: how high celebrity profile can have a major impact on provision of cancer related services , 2014, Breast Cancer Research.

[3]  V. S. Gordeev,et al.  Cost-effectiveness of Population-Based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 Mutation Testing in Unselected General Population Women , 2018, Journal of the National Cancer Institute.

[4]  M. Morrow,et al.  Treatment Decision Making and Genetic Testing for Breast Cancer: Mainstreaming Mutations. , 2015, JAMA.

[5]  Nazneen Rahman,et al.  Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutations , 2002, Nature Genetics.

[6]  M. Morrow,et al.  Association of Attending Surgeon With Variation in the Receipt of Genetic Testing After Diagnosis of Breast Cancer , 2018, JAMA surgery.

[7]  Tom Walsh,et al.  Inherited Mutations in Women With Ovarian Carcinoma. , 2016, JAMA oncology.

[8]  Yahiya Y. Syed.  Rucaparib: First Global Approval , 2017, Drugs.

[9]  J. Baselga,et al.  Multicenter Phase II Study of Lurbinectedin in BRCA-Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment Substudy , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Alice S Whittemore,et al.  Prevalence of pathogenic BRCA1 mutation carriers in 5 US racial/ethnic groups. , 2007, JAMA.

[11]  Claudia X. Aguado Loi,et al.  Utilization and Outcomes of BRCA Genetic Testing and Counseling in a National Commercially Insured Population: The ABOUT Study. , 2015, JAMA oncology.

[12]  Yuya Kobayashi,et al.  Clinical evaluation of a multiple-gene sequencing panel for hereditary cancer risk assessment. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Rakesh R. Patel,et al.  Underdiagnosis of Hereditary Breast Cancer: Are Genetic Testing Guidelines a Tool or an Obstacle? , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Alexander Gutin,et al.  Breast and Ovarian Cancer Penetrance Estimates Derived From Germline Multiple-Gene Sequencing Results in Women. , 2017, JCO precision oncology.

[15]  Bale,et al.  Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.

[16]  Raymond M. Moore,et al.  Association Between Inherited Germline Mutations in Cancer Predisposition Genes and Risk of Pancreatic Cancer , 2018, JAMA.

[17]  Julie O. Culver,et al.  Prospective Study of Cancer Genetic Variants: Variation in Rate of Reclassification by Ancestry , 2018, Journal of the National Cancer Institute.

[18]  L. Bernstein,et al.  Characteristics of triple-negative breast cancer in patients with a BRCA1 mutation: results from a population-based study of young women. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Karla Bowles,et al.  Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next‐generation sequencing with a 25‐gene panel , 2015, Cancer.

[20]  P. Ang,et al.  Breast-cancer risk in families with mutations in PALB2. , 2014, The New England journal of medicine.

[21]  Raymond M. Moore,et al.  Triple-Negative Breast Cancer Risk Genes Identified by Multigene Hereditary Cancer Panel Testing , 2018, Journal of the National Cancer Institute.

[22]  M. King,et al.  Population-based screening for BRCA1 and BRCA2: 2014 Lasker Award. , 2014, JAMA.

[23]  Anjali D. Zimmer,et al.  Cascade Genetic Testing of Relatives for Hereditary Cancer Risk: Results of an Online Initiative , 2018, Journal of the National Cancer Institute.

[24]  Joseph D. Janizek,et al.  Accurate classification of BRCA1 variants with saturation genome editing , 2018, Nature.

[25]  Ahmet Zehir,et al.  Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. , 2016, The New England journal of medicine.

[26]  Reshma Jagsi,et al.  Gaps in Receipt of Clinically Indicated Genetic Counseling After Diagnosis of Breast Cancer. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  James M Ford,et al.  Racial/ethnic differences in multiple-gene sequencing results for hereditary cancer risk , 2017, Genetics in Medicine.

[28]  Julian Peto,et al.  Identification of the breast cancer susceptibility gene BRCA2 , 1996, Nature.

[29]  S. Domchek,et al.  Health Care Segregation, Physician Recommendation, and Racial Disparities in BRCA1/2 Testing Among Women With Breast Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  Peter Szolovits,et al.  Genetic Misdiagnoses and the Potential for Health Disparities. , 2016, The New England journal of medicine.

[31]  Sitao Wu,et al.  Association of Breast and Ovarian Cancers With Predisposition Genes Identified by Large-Scale Sequencing , 2019, JAMA oncology.

[32]  C. Turnbull,et al.  Consensus for genes to be included on cancer panel tests offered by UK genetics services: guidelines of the UK Cancer Genetics Group , 2018, Journal of Medical Genetics.

[33]  K. Nathanson,et al.  Patient feedback and early outcome data with a novel tiered-binned model for multiplex breast cancer susceptibility testing , 2015, Genetics in Medicine.

[34]  M. Robson,et al.  American Society of Clinical Oncology Policy Statement Update: Genetic and Genomic Testing for Cancer Susceptibility. , 2010, Journal of Clinical Oncology.

[35]  Angela DeMichele,et al.  Prevalence of mutations in a panel of breast cancer susceptibility genes in BRCA1/2 negative patients with early onset breast cancer , 2014, Genetics in Medicine.

[36]  A. Kurian,et al.  Multigene Panel Testing in Oncology Practice: How Should We Respond? , 2015, JAMA oncology.

[37]  L. Scott.  Niraparib: First Global Approval , 2017, Drugs.

[38]  Steven E. Bayer,et al.  A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. , 1994, Science.

[39]  Liang Zhao,et al.  FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy , 2015, Clinical Cancer Research.

[40]  Yue Guan,et al.  The Angelina effect: immediate reach, grasp, and impact of going public , 2013, Genetics in Medicine.

[41]  R. Jagsi,et al.  Genetic Testing and Counseling Among Patients With Newly Diagnosed Breast Cancer , 2017, JAMA.

[42]  S. Manley,et al.  Prevalence of Variant Reclassification Following Hereditary Cancer Genetic Testing , 2018, JAMA.

[43]  John Kidd,et al.  Frequency of Germline Mutations in 25 Cancer Susceptibility Genes in a Sequential Series of Patients With Breast Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  Practice Bulletin No 182: Hereditary Breast and Ovarian Cancer Syndrome. , 2017, Obstetrics and gynecology.

[45]  Seth M. Noar,et al.  Cancer Information Seeking in the Digital Age , 2015, Medical decision making : an international journal of the Society for Medical Decision Making.

[46]  Robert Huether,et al.  Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer , 2017, JAMA oncology.

[47]  W. Eiermann,et al.  Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation , 2018, The New England journal of medicine.

[48]  Yuya Kobayashi,et al.  Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment. , 2015, JAMA oncology.

[49]  S. Loi,et al.  Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. , 2017, New England Journal of Medicine.

[50]  Tina Pesaran,et al.  Utilization of multigene panels in hereditary cancer predisposition testing: analysis of more than 2,000 patients , 2014, Genetics in Medicine.

[51]  K. Offit,et al.  Gene patents and personalized cancer care: impact of the Myriad case on clinical oncology. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  R. Jagsi,et al.  Uptake, Results, and Outcomes of Germline Multiple-Gene Sequencing After Diagnosis of Breast Cancer , 2018, JAMA oncology.

[53]  W. Blot,et al.  BRCA1 and BRCA2 Testing in Medically Underserved Medicare Beneficiaries With Breast or Ovarian Cancer , 2018, JAMA.

[54]  O. Kallioniemi,et al.  A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer. , 2002, American journal of human genetics.

[55]  S. Narod,et al.  Population-Based Genetic Testing for BRCA1 and BRCA2. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  B. Ward,et al.  BRCA1 and BRCA2 mutations in women of different ethnicities undergoing testing for hereditary breast‐ovarian cancer , 2009, Cancer.